Novo Holdings A/S’s OnKure Therapeutics OKUR Stock Holding History

Novo Holdings A/S’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-333,038	Closed	-$25.3M	–	39
2023 Q3	$25.3M	Hold	333,038	–	–	1.87%	22
2023 Q2	$21.8M	Sell	333,038 -10,000	-3%	-$806K	1.69%	21
2023 Q1	$20.5M	Hold	343,038	–	–	1.35%	23
2022 Q4	$7.99M	Hold	343,038	–	–	0.5%	39
2022 Q3	$11.5M	Hold	343,038	–	–	0.55%	32
2022 Q2	$9.09M	Hold	343,038	–	–	0.45%	40
2022 Q1	$10.1M	Hold	343,038	–	–	0.53%	33
2021 Q4	$29.3M	Hold	343,038	–	–	1.39%	15
2021 Q3	$25.6M	Hold	343,038	–	–	1.32%	18
2021 Q2	$32M	Buy	+343,038	New	+$38.3M	1.42%	19

Other funds holding OKUR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

RVM

RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Novo Holdings A/S's OKUR Position: Q4 2023 in Review

Novo Holdings A/S sold out of OnKure Therapeutics (OKUR) in Q4 2023, closing a stake of 333,038 shares — an estimated $25.3M sold.

Novo Holdings A/S first reported a position in OKUR in Q2 2021 and held it in 10 quarters. The position peaked at $32M in Q2 2021. 68 funds tracked by Wall St. Rank hold OKUR as of Q4 2023.

Novo Holdings A/S reported no remaining OnKure Therapeutics position as of Q4 2023 after selling out during the quarter.
Novo Holdings A/S sold 333,038 OnKure Therapeutics shares in Q4 2023, an estimated $25.3M.
Novo Holdings A/S first reported a position in OnKure Therapeutics in Q2 2021 and held it in 10 quarters.
Novo Holdings A/S's OnKure Therapeutics position peaked at $32M in Q2 2021.
68 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q4 2023.

Based on Novo Holdings A/S's 13F filing for Q4 2023, filed 14 Feb 2024.